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In liver transplantation (LT), both recipients and donors are getting older. According to the recent data by the 
Scientific Registry of Transplant Recipients (SRTRs), the 
number of LT recipients who were ≥65 years almost tripled 
from 2007 to 2017 (n = 648 in 2007, n = 1674 in 2017, 
2.6-fold increase).1 This increase was also reflected in the 
percentage of overall adult LT population. In 2007, while 
only 11% of all LT recipients were ≥65 years old, in 2017 
it was 22.4% (100% increase).1 In fact, the waiting list for 
LT mirrors the above picture. With improved diagnostics, 
better patient management, and newer and more efficient 
pharmacological agents, there are an increasing number of 
older patients with end-stage liver disease who have been 
benefitting and will continue to benefit from LT. According 
to the census.gov, the estimated percentage increase in pop-
ulation in the United States projects that older population 
≥65 years will increase 48% by 2030 and 74% by 2050.2 
On the other hand, there is a projection that the size of 
mid-age population (45–64 y) will have a drop of 3.5% 
by 2030, and there will only be 13% increase by 2050 
(Figure 1).
There are several single-center or SRTR reports analyz-
ing the impact of recipient age in LT, especially in regard to 
elderly recipients who were ≥65 years old3 or ≥70 years old.4-7 
A decade ago, a single-center report from the Mayo Clinic 
showed in a cohort of 42 patients that 5-year mortality and 
graft loss in elderly recipients (≥70 y) in LT were comparable 
with those in younger recipients (<60 y).7 More recent reports 
with larger cohorts (SRTR analyses)4,5 showed that patient 
survival in elderly recipients (≥70 y) was significantly lower 
in an unadjusted analysis. However, Wilson et al5 reported 
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at 1 (60%) and 3 years (40%) (P = 0.0077). Control analyses (replicating Scientific Registry of Transplant Recipient’s survival 
stratification: 18–45, 46–64, ≥65 y) showed similar patient survival in all age groups. Conclusions. Although LT can be 
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similar patient survival in elderly recipients with those who 
were 18–69 y old in an “adjusted” (1:1) case-match analysis.
Elderly recipients may carry a higher risk when it comes 
to the combined liver-kidney transplantation (CLKT, simul-
taneous liver-kidney transplantation) due to the magnitude of 
operation and higher chances of delayed graft function (DGF) 
of the transplanted kidney, which significantly correlates with 
patient’s mortality in CLKT.8,9 A recent report from Croome 
et al10 analyzed the SRTR data between 2002 and 2015 on 
patients undergoing CLKT who were ≥65 years (n = 677) and 
<65 years (n = 4517). The authors found that both older (≥65 
y) and younger (<65 y) recipients have similar patient and 
graft survival. Recent discussions at national and interna-
tional LT congresses in 2019 tried to identify the appropriate 
age cutoff for the CLKT. However, there are limited published 
data on elderly recipients (≥70 y) undergoing CLKT.11 In the 
present study, we sought to identify the outcomes of elderly 
recipients undergoing CLKT using a homogenous cohort in a 
high-volume transplant center.
MATERIALS AND METHODS
Medical records of all patients who underwent CLKT 
between June 2007 to October 2018 at Indiana University 
Hospital were reviewed. Inclusion criteria for the data 
analysis included all adult (≥18 y old) transplant recipients 
undergoing CLKT, including kidney or liver retransplants. 
No exclusions were granted for intraoperative or perio-
perative mortality or graft loss, for nontransplant-related 
deaths, or for noncompliance. Retrospective review and 
analysis of data from the transplant center database was 
approved by the Institutional Review Board of Indiana 
University School of Medicine.
Indications and Definitions
All CLKTs were performed using the Indiana Approach 
technique (see below) [9]. CLKTs performed using “simulta-
neous” liver-kidney transplantation before June 2007 were 
excluded to avoid the era effect and focus on a homogenous 
cohort of patients who received the CLKT under the same 
surgical technique and clinical experience in patient manage-
ment. Recipient listing for CLKT was according to standard 
criteria and protocols as established by our center and United 
Network for Organ Sharing, which was recently updated in 
2016.12 Before 2016, patients who required CLKT were listed 
according to their eGFR <30 mL/min/1.73 m2 calculated 
by the modification of diet in renal disease formula before 
transplant for chronic renal failure or their need for dialy-
sis for >8 weeks, as proposed by United Network for Organ 
Sharing.13,14 DGF was defined as the need for dialysis within 
the first 7 days following kidney transplantation. Kidney graft 
failure was defined as removal of the graft or complete loss of 
graft function requiring retransplantation or permanent dialy-
sis. Graft function was monitored clinically and by laboratory 
values (serum creatinine and eGFR).
Four different recipient age groups (18–45, 46–59, 60–69, 
and ≥70 y) were defined to study the real impact of recipi-
ent age. The SRTR data were used to compare the national 
outcomes with our center.10,15 In order to replicate the SRTR 
recipient age stratification (18–45, 46–64, and ≥65 y), a con-
trol analysis was ran using the 3 different age subgroups 
instead of 4 age subgroups.
Surgical Technique—Indiana Approach
Organ procurements (brain dead or donation after circu-
latory death [DCD] donors) were performed using standard 
surgical techniques and cold preservation.9,16-18 Details of the 
Indiana Approach have been reported previously.9,19-22 Briefly, 
to accommodate physiological needs for both liver and kid-
ney allografts, LT is performed first while the kidney graft is 
placed on a hypothermic pulsatile perfusion machine. At our 
center, all deceased kidney allografts, regardless of their allo-
cation as CLKT, kidney transplantation alone, or simultane-
ous pancreas and kidney transplant, are routinely maintained 
on continuous hypothermic pulsatile machine perfusion 
(Waters IGL perfusion machine) (Waters Medical Systems, 
Rochester, MN).18 Implantation of the kidney graft is usually 
delayed for 2 to 3 days post-LT which allows stabilization of 
LT patients’ hemodynamics and coagulopathy in the post-LT 
period, before implantation of the renal allograft. All recipi-
ents of CLKT are also supported by continuous venovenous 
hemodialysis initiated at the time of LT and continued during 
the intensive care unit until the kidney transplant is complete.
Immunosuppressive Therapy and Infection 
Prophylaxis
Details of the immunosuppressive regimen and prophy-
laxis protocol in CLKT recipients have been reported pre-
viously.9,19,21 Briefly, induction therapy included rabbit 
antithymocyte globulin (rATG) (2 mg/kg for 3 doses), and 
anti-CD20 monoclonal antibody (Rituximab, single dose 
1.5 mg/m2, maximum 300 mg), only in case of increased immu-
nologic risk. rATG was administered before the implantation 
FIGURE 1. Projected percentage increase in population in the United 
States by 2050. X represents 2016, and all other y show percentage 
increase or decrease in national population compared with 2016. 
Eighteen to 44 age group will increase 2.8%, 7.7%, 9%, and 12%. 
Forty-five to 64 age group will increase −1%, −3.5%, 5.8%, and 13%. 
Age group 18–64 will increase 1.2%, 3%, 7.7%, and 12.3%. Age 
group ≥65 will increase 13.8, 48%, 64%, and 74%. Age group ≥85 
will increase 5%, 42%, 126%, and 191%. Census.gov: https://www.
census.gov/data/tables/2017/demo/popproj/2017-summary-tables.
html.
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of the kidney allograft on postoperative day 1 or 2, depend-
ing on recipient’s hemodynamic stability. Almost all elderly 
recipients ≥70 years were excluded from the rATG induction, 
and they only received methylprednisolone 500 mg induction 
for 3 days and discontinued completely. For recipients 18–69 
years old, a methylprednisolone bolus was administered as 
premedication for each of the 3 rATG infusions and then was 
discontinued completely. Maintenance immunosuppressive 
therapy included tacrolimus (target trough levels of 7–10 ng/
dL for the first 3 mo posttransplant, and 6–8 ng/mL, thereaf-
ter) and mycophenolate mofetil (1000 mg BID).
Statistical Analysis and End Points
The primary end point was patient survival after CLKT in 
all age groups. The data were summarized using means with 
SDs, or medians with interquartile ranges for continuous 
variables, and percentages for discrete variables. Continuous 
variables were analyzed using Wilcoxon-Mann-Whitney test. 
For discrete variables, the ANOVA analysis was performed 
unless the event number for the given group was ≤5, in which 
case Fisher exact test was performed. Patient survival prob-
ability was estimated using the Kaplan-Meier method, and 
differences in the curves were analyzed using a log-rank 
test. All statistical calculations were performed by IBM SPSS 
MacOs version (v1.0.0.701, NY). Images were created using 
GraphPad Prism 8 for MAC OS X (La Jolla, CA). A P value of 
<0.05 was considered statistically significant.
RESULTS
Donor and recipient demographics were comparable 
within all groups including kidney donor profile index score, 
the ratio of extended criteria donor and DCD kidneys, pre-
vious liver and kidney transplants, model for end-stage liver 
disease (MELD) score, and donor-model for end-stage liver 
disease score, except recipient age, as expected. However, 
elderly patients stayed longer on dialysis (median: 405 d) 
compared with younger age groups (P < 0.05) (Table 1). All 
CLKTs were performed using the Indiana Approach; there-
fore, mean kidney cold ischemia time was comparable in all 
groups (≈53 h, P = not significant). Mean liver cold ischemia 
time was also similar and was kept below 6 hours in all age 
groups (Table 2).
Although DGF of transplanted kidneys was much lower 
compared with literature (overall 4% in our series),23,24 it 
was 25% in elderly (≥70 y) patients and significantly higher 
compared with younger recipients (P = 0.017). Intensive care 
unit stay and overall hospital stay were significantly longer in 
elderly recipients compared with younger recipients (Table 2). 
In group 4 (Table  2), there were 2 early deaths (2/8, 25%) 
within 7 days post-CLKT and it was significantly higher 
compared with younger recipients (P < 0.001). Both recipi-
ents died on postoperative day 5. In the first early death (72-
y-old male), the transplanted kidney never worked and had 
primary nonfunction. He died due to stress cardiomyopathy 
despite attempted ECMO support. In the second early death 
(72-y-old female), the patient developed an acute respiratory 
distress syndrome and she died with functioning liver and 
kidney grafts. Causes of death in all age groups are reported 
in Table  3. The main cause of death was cardiovascular 
(6 cases in age groups 46 and higher). Though, we believe car-
diovascular reasons would be even higher because 8 deaths 
were reported as “unknown” as they happened at home with 
no known cause. In the youngest age group (18–45 y), we 
observed a noncompliance issue in a 38-year-old recipient and 
he eventually died with rejection and damage to the liver due 
to alcohol consumption. Although the percentage of deaths 
was comparable between groups within 1 year posttransplant 
(Table 2), at 3 years, Kaplan-Meier survival was significantly 
lower in elderly patients ≥70 years (log-rank test P = 0.0077) 
(Figure 2A).
Control Analyses Using the SRTR Age Stratification
We ran a separate control analyses (1) to replicate SRTR’s 
recipient age stratification and (2) also to compare our cohort 
with the published literature. For this reason, Kaplan-Meier 
patient survival curves were calculated based on 3 different 
age groups (18–45, 46–64, and ≥65 y).1,10 We observed that 
patient survival at 3 years post-CLKT was comparable in all 
age groups (P = 0.2420) (Figure  2B), as it was observed by 
Croome et al10 in their SRTR analysis with CLKT.
DISCUSSION
The face of LT has changed in the last decades. The num-
ber of LTs performed each year in the United States and in 
Europe increased together with improved patient survival post-
LT.25 The potential pool of transplantable livers has enlarged 
due to a growing number of DCD LT which is expanded by 
using extended criteria DCD donors that have compara-
ble outcomes to standard brain dead donors.26 As a result of 
improved outcomes, LT is currently being offered to older and 
sicker patients. With the aging population, it is inevitable that 
patients with end-stage liver disease and those undergoing LT 
will get older. In fact, SRTR data showed a 100% increase of 
the percentage of LT recipients who were ≥65 years from 2007 
to 2017.1 As indicated by the census.gov data, we have to face 
even a worse situation within 30 years by 2050 (Figure 1).2 It is 
also well-known that there is a substantial loss of nephrons in 
healthy human kidneys with aging.27 Thus, the elderly popula-
tion is more susceptible to kidney failure and elderly patients 
with end-stage liver disease will face higher chances of chronic 
kidney disease and therefore will require more CLKT.
What Is the Age Cutoff for CLKT?
Debates on the identification of age cutoff for LT and 
especially CLKT have been ongoing. Several studies 
reported mix outcomes in elderly recipients undergoing LT.4-
6 Although recent SRTR data showed that LT can be safely 
performed in elderly recipients ≥70 years with comparable 
outcomes as in younger recipients (18–69 y),5 patients need-
ing CLKT tend to be sicker than those needing LT alone 
and carry higher risk. Another recent SRTR analysis studied 
the impact of recipient age in CLKTs.10 This SRTR study 
spanned between 2002 and 2015 with 573 patients in the 
age group 65 and 69 years and 104 patients in the age group 
≥70 years,10 but there was no detailed analysis for the age 
group ≥70 years. The authors came up with a scoring system 
based on multivariate analysis outcomes which indicated 
(1) MELD score (per 5 points increments), (2) recipient age 
≥70 years, and (3) being on the ventilator at the time of 
CLKT significantly impacted the patient survival negatively. 
In fact, the authors stated that “using the scoring system,” 
CLKT should be avoided in patients ≥65 years of age on 
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a mechanical ventilation before CLKT and in patients ≥70 
years of age with a MELD score ≥30.10 However, the overall 
message was that outcomes of CLKT in patients ≥65 years 
compared with <65 years and also compared with ≥65 years 
receiving LT alone were similar.
We believe that this was due to the number of CLKT 
recipients between 65 and 69 y which made 85% of the 
studied SRTR population (573/677, 85%, ≥65 y).10 Our 
control analyses with the SRTR age stratification showed 
the similar patient survival in CLKT among age groups 
TABLE 1.
Donor and recipient demographics in combined liver-kidney transplantation using the Indiana Approach
Total (n = 98)
Group 1  
(age 18–45) (n = 16)
Group 2  
(age 46–59) (n = 34)
Group 3  
(age 60–69) (n = 40)
Group 4  
(age ≥70) (n = 8) P
Recipient demographics  
 Age (mean ± SD), y 57 ± 12 35 ± 9 55 ± 4 65 ± 3 73 ± 3 <0.001
 Gender (n, %)      n.s.
  Male 58, 59% 9, 56% 21, 62% 24, 60% 4, 50%  
  Female 40, 41% 7, 44% 13, 38% 16, 40% 4, 50%  
 Race (n, %)      n.s.
  White 85, 87% 14, 88% 31, 91% 33, 83% 7, 88%  
  African American 7, 7% 1, 6% 2, 6% 4, 10% 0, 0%  
  Other 6, 6% 1, 6% 1, 3% 3, 7% 1, 12%  
 Blood type (n, %)      n.s.
  A 57, 45% 5, 32% 14, 41% 15, 38% 2, 25%  
  B 14, 10% 2, 12% 6, 18% 6, 14% 2, 25%  
  AB 5, 4% 1, 6% 1, 3% 0, 0% 0, 0%  
  O 54, 41% 8, 50% 13, 38% 19, 48% 4, 50%  
 Body mass index (mean ± SD), kg/m2 27 ± 5 29 ± 5 27 ± 5 27 ± 5 26 ± 3  
 Primary indication for transplant (n, %)      n.s.
  ETOH 19, 19% 4, 25% 10, 29% 5, 13% 0, 0%  
  Hepatitis C 24, 24% 0, 0% 9, 26% 15, 38% 0, 0%  
  Autoimmune liver disease 12, 12% 3, 19% 4, 12% 2, 3% 3, 38%  
  NASH 22, 22% 0, 0% 5, 15% 13, 33% 4, 50%  
  Other 21, 21% 9, 56% 6, 18% 5, 13% 1, 12%  
 Hepatitis C positivity (n, %) 32, 32% 1, 6% 13, 38% 18, 45% 0, 0%  
 All diabetes (n, %) 34, 35% 5, 32% 11, 32% 15, 38% 3, 38% n.s.
 Cytomegalovirus status (n, %)      n.s.
  D−/R− 12, 12% 3, 19% 7, 20% 1, 3% 1, 12%  
  D−/R+ 24, 24% 3, 19% 8, 24% 10, 25% 3, 38%  
  D+/R− 19, 19% 2, 12% 7, 20% 8, 20% 2, 25%  
  D+/R+ 43, 43% 8, 50% 12, 36% 21, 52% 2, 25%  
 MELD (mean ± SD) 28 ± 7 30 ± 8 28 ± 8 27 ± 7 26 ± 6 n.s.
 D-MELD (mean ± SD) 960 ± 481 846 ± 465 1033 ± 515 956 ± 487 905 ± 339 n.s.
 Previous kidney transplant (n, %) 5, 5% 4, 25% 0, 0% 1, 3% 0, 0% n.s.
 Previous liver transplant (n, %) 7, 7% 2, 13% 1, 3% 4, 10% 0, 0% n.s.
 Dialysis before transplant (%) 63% 75% 62% 55% 50% n.s.
 Duration of dialysis before transplant (median), d 180 180 360 360 405 <0.05
 Duration of eGFR <30 mL/min/1.73 m2 for patients  
 who were not on dialysis (median), d
90 90 105 105 90 n.s.
Donor demographics  
 Age (mean ± SD), y 34 ± 13 28 ± 11 35 ± 12 35 ± 14 35 ± 12 n.s.
 Gender (n, %)      n.s.
  Male 60, 60% 10, 62% 20, 59% 24, 60% 6, 75%  
  Female 38, 40% 6, 38% 14, 41% 16, 40% 2, 25%  
 Body mass index (mean ± SD), kg/m2 27 ± 6 24 ± 5 27 ± 7 27 ± 5 29 ± 6 n.s.
 Cause of death (n, %)      n.s.
  Stroke 19, 19% 3, 19% 6, 18% 8, 20% 2, 25%  
  Trauma 46, 47% 10, 62% 13, 38% 19, 48% 4, 50%  
  Anoxia/Other 33, 34% 3, 19% 15, 44% 13, 32% 2, 25%  
 Donor hepatitis C positivity (n, %) 5, 5% 0, 0% 1, 3% 4, 10% 0, 0% n.s.
 Extended criteria donor kidneys (n, %) 10, 10% 2, 12% 1, 3% 7, 18% 1, 12% n.s.
 Donation after circulatory death kidneys (n, %) 7, 7% 0, 0% 3, 10% 3, 7% 1, 12% n.s.
 Donor KDPI (mean ± SD) (range) 33 ± 23 (1–92) 24 ± 20 (3–80) 35 ± 23 (1–79) 34 ± 24 (1–92) 30 ± 20 (6–71) n.s.
D, donor; D-MELD, donor-model for end-stage liver disease; eGFR, estimated glomerular filtration rate; ETOH, alcoholic liver disease; KDPI, kidney donor profile index; MELD, model for end-stage liver 
disease; n.s, not significant; NASH, nonalcoholic steatohepatitis; R, recipient.
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18–45, 46–64, and ≥65 years (Figure 2B). The similar trend 
in the number of patients between 65 and 69 years (20/28, 
71%, ≥65 y) was also seen in our cohort. Therefore, we 
believe if the recipient age stratification is kept as <65 
and ≥65 years, good outcomes in the increased number of 
CLKT between 65 and 69 years will absorb the unfavora-
ble outcomes in elderly recipients ≥70 years.
To understand the true impact of recipient age in CLKT in 
patients ≥70 years, we grouped recipients in 4 different age 
groups. Elderly recipients (≥70 y) showed the worse patient 
survival at 3 years following CLKT (Figure 2). Although cir-
culatory source of mortality was expected, we observed only 
1 death from cardiovascular complications in patients ≥70 
years. Moreover, of 6 cardiovascular deaths seen in all recipi-
ents, 3 of them were in the age group 60–69 years (Table 3). 
Although 2 early deaths (within a wk post-CLKT) signifi-
cantly impacted the survival rate of patients ≥70 years (2/8, 
25%), it was still better than the SRTR data, which shown 
50% higher mortality among recipients ≥70 years of age with 
a hazard ratio of 1.6.10
Limitations
Our study has some limitations. First of all, it is a retro-
spective cohort study. Although the percentage of recipi-
ents ≥70 years in CLKT was 4-fold more compared with 
the SRTR (8.2% at our center versus 2% SRTR), the total 
number was only 8 patients. Considering that the SRTR had 
only 96 CLKT recipients who were ≥70 years in 12 years 
(2007–2018, same study period as the current study), our 
case series makes up 8.3% of the SRTR cohort. The technique 
for CLKT was the Indiana Approach which has been adopted 
by some US and European centers most recently.28,29 Overall 
surgical technique (Indiana Approach), immunosuppressive 
regimen, and patient management were similar for the studied 
cohort, however with time; we probably became more adept 
in managing sicker recipients. Although percentage of patients 
on dialysis before CLKT was similar among all age groups, 
recovery of native renal function following CLKT30 could be 
a factor for better outcomes especially in younger recipients 
with better preserved nephron mass.27 Moreover, the liver 
allocation system was changed from MELD 15 to Share 35 
and most recently with mandatory CLKT (simultaneous liver-
kidney transplantation) policy,12 impacting the allocation of 
CLKT throughout the study period as well. Lastly, we did not 
include the frailty scale of recipients in the outcomes due to 
the 12-year study cohort.
In conclusion, we believe that our study plays a signifi-
cant role in the ongoing discussions on the decision of age 
cutoff for CLKT and how the true impact of recipient age 
should be studied based on age groups. Although LT alone 
can be safely performed in elderly recipients ≥70 years, cau-
tion is needed in CLKT due to the magnitude of operation 
TABLE 2.




Group 1  
(age 18–45) (n = 16)
Group 2 (age 
46–59) (n = 34)
Group 3 (age 
60–69) (n = 40)
Group 4  
(age ≥70) (n = 8) P
Cold ischemia time (h) (mean ± SD)       
 Kidney 53 ± 14 54 ± 14 50 ± 16 54 ± 12 59 ± 7 n.s.
 Liver 5.6 ± 1.3 6.0 ± 1.7 5.6 ± 1.4 5.5 ± 0.9 5.4 ± 1.5 n.s.
Warm ischemia time (min) (mean ± SD)       
 Kidney 38 ± 9 37 ± 7 39 ± 11 38 ± 8 38 ± 7 n.s.
 Liver 20 ± 4 21 ± 4 20 ± 4 19 ± 5 22 ± 4 n.s.
Delayed graft function of renal grafts (n, %) 4, 4% 0, 0% 1, 3% 1, 3% 2, 25% 0.017
Intensive care unit stay (mean ± SD) (range) 
(median), da
14 ± 21 (2–92) (6.5) 21 ± 35 (2–134) (7.5) 13 ± 17 (2–92) (5.5) 10 ± 14 (2–70) (5) 20 ± 23 (6–73) (12.5) <0.001
Hospital stay (mean ± SD) (median), da 35 ± 48 (6–399) 
(21.5)
37 ± 40 (6–151) (22.5) 32 ± 33 (8–146) (21) 36 ± 63 (7–399) (20) 36 ± 29 (6–92) (30.5) <0.001
Death within 7 d posttransplantation (n, %) 2, 2% 0, 0% 0, 0% 0, 0% 2, 25% <0.001
Death within 90 d posttransplantation (n, %) 7, 7% 2, 13% 3, 10% 0, 0% 2, 25% 0.052
Death within 1 y posttransplantation (n, %) 13, 14% 3, 19% 3, 10% 4, 10% 3, 38% n.s.






Group 1  
(age 18–45) (n = 16)
Group 2  
(age 46–59) (n = 34)
Group 3  
(age 60–69) (n = 40)
Group 4  
(age ≥70) (n = 8)
Cardiovascular 6  2 3 1
Acute respiratory distress syndrome 1    1
Cancer 1   1  
Noncompliance 1 1    
Liver failure (including primary nonfailure) 2 1   1
Other/unknown 8 1 1 5 1
Total deaths throughout follow-up 19 3 3 9 4
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and expected inferior outcomes, despite delayed kidney 
transplantation in CLKT (Indiana Approach) which was 
shown to offer excellent patient survival.9,19-22,28,29 Further 
studies with larger cohorts are needed to determine the 
true age cutoff for CLKT and what the future will be since 
we cannot ignore the aging population in LT.
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